Christiana Stamoulis
United States
0
years old
Christiana Stamoulis is a senior executive in the biopharmaceutical industry, with extensive experience in developing strategies for sustainable, profitable growth, and expertise in the execution of complex M&A deals, strategic collaborations and corporate finance transactions that aim to help companies achieve their corporate goals.
Christiana Stamoulis brings nearly 20 years of experience in the healthcare industry as a strategic advisor to CEOs and Board of Directors of global pharmaceutical and biotech companies, a senior executive with Vertex Pharmaceuticals and an independent director of the Board of Hologic.
As a member of Vertex Pharmaceuticals Executive Team and Senior Vice President and head of Corporate Strategy and Business Development, she helped develop Vertex’s corporate vision of the future and led the development of strategies and initiatives to achieve this vision and drive the company's long-term growth. She also identified and executed key business collaborations to help Vertex achieve its strategic objectives, including collaborations to achieve Vertex’s goal of developing an all-oral regimen for treating Hepatitis C, and to discover and develop additional drugs aimed at treating Cystic Fibrosis. Christiana was the architect of Vertex’s global collaboration with Alios Biopharma that allowed Vertex to gain worldwide rights to VX-135, it's foundation asset for the development of all-oral HCV therapies, and of the most recent collaboration with the Cystic Fibrosis Foundation to accelerate the discovery and development of new therapies.
Christiana Stamoulis’s strategic expertise and extensive experience in the healthcare industry and in executing initiatives for growth enable her to also provide valuable insights to the Board of Hologic Inc., a leading global developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products, where she serves as an independent director of the Board.
As a member of Vertex Pharmaceuticals Executive Team and Senior Vice President and head of Corporate Strategy and Business Development, she helped develop Vertex’s corporate vision of the future and led the development of strategies and initiatives to achieve this vision and drive the company's long-term growth. She also identified and executed key business collaborations to help Vertex achieve its strategic objectives, including collaborations to achieve Vertex’s goal of developing an all-oral regimen for treating Hepatitis C, and to discover and develop additional drugs aimed at treating Cystic Fibrosis. Christiana was the architect of Vertex’s global collaboration with Alios Biopharma that allowed Vertex to gain worldwide rights to VX-135, it's foundation asset for the development of all-oral HCV therapies, and of the most recent collaboration with the Cystic Fibrosis Foundation to accelerate the discovery and development of new therapies.
Christiana Stamoulis’s strategic expertise and extensive experience in the healthcare industry and in executing initiatives for growth enable her to also provide valuable insights to the Board of Hologic Inc., a leading global developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products, where she serves as an independent director of the Board.
Christiana Stamoulis began her professional career as a strategy consultant with The Boston Consulting Group. In this role, she advised clients on projects involving major strategy and organizational change and developed strategies to enable them to achieve their corporate objectives, build more capable organizations and generate sustainable and profitable growth.
After a number of years as a strategy consultant, she moved to the investment banking industry where she joined Goldman, Sachs & Co.’s Healthcare Investment Banking group. As an investment banker, she focused on advising CEOs, CFOs and Board of Directors of global pharmaceutical and biotech companies on key strategic and corporate finance decisions. Christiana Stamoulis also led the execution of several industry-defining M&A deals, including such notable deals as Amgen's $16 billion acquisition of Immunex; Biogen's $14 billion merger-of-equals with IDEC Pharmaceuticals; American Pharmaceutical Partners' $7 billion merger with American Bioscience; and Shire's $2 billion acquisition of Transkaryotic Therapies.
In 2006, she was recruited by Citigroup to help build the Company's Life Sciences Investment Banking practice. While at Citigroup, she advised several leading biopharmaceutical companies, including the NY-based Bristol Myers-Squibb for which she executed a number of M&A, divestiture and spin-off transactions that aimed at sharpening the Company’s BioPharma focus, improve its overall financial strength and enhance its long-term growth profile.
She has brought to her clients extensive experience in developing strategies for sustainable, profitable growth, in identifying attractive growth avenues and in executing complex transactions across products in order to help them achieve their strategic goals. She has advised clients and has led the execution of M&A and capital raising deals with aggregate value in excess of $100 billion.
Christiana Stamoulis is a graduate of the Massachusetts Institute of Technology. She holds two Bachelor of Science degrees from MIT, including a Bachelor of Science in Economics, and a Masters in Business Administration from the MIT Sloan School of Management, with a concentration in finance and applied economics.
After a number of years as a strategy consultant, she moved to the investment banking industry where she joined Goldman, Sachs & Co.’s Healthcare Investment Banking group. As an investment banker, she focused on advising CEOs, CFOs and Board of Directors of global pharmaceutical and biotech companies on key strategic and corporate finance decisions. Christiana Stamoulis also led the execution of several industry-defining M&A deals, including such notable deals as Amgen's $16 billion acquisition of Immunex; Biogen's $14 billion merger-of-equals with IDEC Pharmaceuticals; American Pharmaceutical Partners' $7 billion merger with American Bioscience; and Shire's $2 billion acquisition of Transkaryotic Therapies.
In 2006, she was recruited by Citigroup to help build the Company's Life Sciences Investment Banking practice. While at Citigroup, she advised several leading biopharmaceutical companies, including the NY-based Bristol Myers-Squibb for which she executed a number of M&A, divestiture and spin-off transactions that aimed at sharpening the Company’s BioPharma focus, improve its overall financial strength and enhance its long-term growth profile.
She has brought to her clients extensive experience in developing strategies for sustainable, profitable growth, in identifying attractive growth avenues and in executing complex transactions across products in order to help them achieve their strategic goals. She has advised clients and has led the execution of M&A and capital raising deals with aggregate value in excess of $100 billion.
Christiana Stamoulis is a graduate of the Massachusetts Institute of Technology. She holds two Bachelor of Science degrees from MIT, including a Bachelor of Science in Economics, and a Masters in Business Administration from the MIT Sloan School of Management, with a concentration in finance and applied economics.
No Bio Specified
Christiana Stamoulis doesn't have any reviews yet
Education
-
MIT Sloan School of Management , United States , 50 Memorial Dr Cambridge, Massachusetts
Masters in Business Administrationmitsloan.mit.edu/01/1994 - 01/1996 -
Massachusetts Institute of Technology , United States , 77 Massachusetts Ave, Cambridge, Massachusetts
Bachelor of Science in Economicsweb.mit.edu/08/1990 - 05/1994 -
Massachusetts Institute of Technology , United States , Cambridge, MA
Bachelor of Science in Architectureweb.mit.edu01/1989 - 01/1992
Career History
-
Director of the Board , United States , Bedford, Massachusetts
www.hologic.com/11/2011 to 12/2099Senior Vice President of Corporate Strategy and Business Development , United States , Cambridge, Massachusetts
www.vrtx.com01/2009 to 12/2099Managing Director, Healthcare Group, Investment Banking Division , United States , New York, Ny
http://icg.citi.com/icg/corporateandinvestmentbanking/invest_banking.jsp01/2006 to 01/2009Vice President, Healthcare Group, Investment Banking Division , United States , New York, NY
www.gs.com01/2000 to 01/2006Consultant , London
www.bcg.comtoFamily & Friends-
United States, Pennsylvania, Philadelphia -
United States, California, San Francisco -
No approved location -
United States, California, San Francisco -
No approved location -
United States, Ohio, Zanesville -
United States, Michigan, Kalamazoo -
United States, California, Laguna Niguel -
United States, Texas, San Angelo
No neighbors Specified
-
United States
-
United States -
United States -
United States, Massachusetts, Cambridge -
United States, Massachusetts, Milton -
United States, Massachusetts, Waban -
United States, Pennsylvania, State College
Core Competencies- Strategy
- Pharmaceutical Industry
- Mergers & Acquisitions
- Strategic Alliances
- Biotechnology
- Corporate Finance
- Corporate Development
- Investment Banking
- Lifesciences
- Capital Markets
Greatest AttributesNo Greatest Attributes Specified
Business AchievementsNo Business Achievements Specified
Worst Failures in BusinessNo Worst Failures in Business Specified
Political PartyNo Political Party Specified
Completed aggregates publicly available information from government, social, and other sources, plus personal reviews written by others. Because Completed only collects this data and does not create it, we cannot fully guarantee its accuracy.